Frontage Holdings Corp
01521
Company Profile
Business description
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
Contact
700 Pennsylvania Drive
ExtonPA19341
USAT: +1 610 232-0100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,540
Stocks News & Analysis
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,712.80 | 44.30 | 0.51% |
| CAC 40 | 7,769.31 | 77.24 | -0.98% |
| DAX 40 | 22,612.97 | 344.11 | -1.50% |
| Dow JONES (US) | 45,960.11 | 469.38 | -1.01% |
| FTSE 100 | 9,972.17 | 134.67 | -1.33% |
| HKSE | 24,980.89 | 124.46 | 0.50% |
| NASDAQ | 21,408.08 | 521.74 | -2.38% |
| Nikkei 225 | 53,373.07 | 230.58 | -0.43% |
| NZX 50 Index | 12,935.39 | 6.09 | 0.05% |
| S&P 500 | 6,477.16 | 114.74 | -1.74% |
| S&P/ASX 200 | 8,516.30 | 44.70 | 0.53% |
| SSE Composite Index | 3,913.72 | 24.64 | 0.63% |